---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-25-000169"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:22:26.908089+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q2 revenue $7.3M (+10% YoY); enters $45M term loan with Trinity Capital

## Summary
- Q2 2025 revenue $7.3M, up 10% YoY; net loss $11.9M ($0.27/sh) vs $12.6M ($0.29) prior year.
- Gross margin turned positive at 4% (vs -3% in Q2 2024); recurring revenue up 15% to $4.4M.
- Reaffirms FY2025 revenue guidance of at least $32.0M.
- Entered $45M term loan facility with Trinity Capital; $20M drawn at close, no financial covenants.
- Initial interest rate 11.5% p.a.; 36-month interest-only period; warrants for 179,104 shares at $3.35/sh.

## SEC filing metadata
- accession: 0001380106-25-000169
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010625000169/0001380106-25-000169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010625000169/rpid-20250808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-25-000169
- JSON: https://secwatch.observer/filing/0001380106-25-000169.json
- Plain text: https://secwatch.observer/filing/0001380106-25-000169.txt

## Key facts
- Debt Financings
  RAPID MICRO BIOSYSTEMS, INC. incurred term loan of $20.0 million with Trinity Capital Inc. at the greater of (a) the sum of (i) The Wall Street Journal Prime Rate and (ii) 4. maturing September 1, 2030.
  - Instrument: term loan
  - Principal: $20.0 million
  - Counterparty: Trinity Capital Inc.
  - Rate: the greater of (a) the sum of (i) The Wall Street Journal Prime Rate and (ii) 4.
  - Maturity: September 1, 2030
  - Event: incurrence
  source text: On August 8, 2025 (the "Closing Date"), Rapid Micro Biosystems, Inc. (the "Company") entered into a Loan and Security Agreement (the "LSA") with the lenders party thereto (the "Lenders") and Trinity Capital Inc., as administrative agent and collateral agent (the "Agent"). Under the LSA, the Lenders agreed to extend debt capital to the Company, in the form of a term loan, in tranches totaling an aggregate principal amount of up to $45.0 million available as follows: (a) at closing, an aggregate principal amount of $20.0 million (the "First Tranche")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010625000169/0001380106-25-000169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.